American Society of Hirudotherapy

Ultrastructural and morphological characterization of Trypanosoma bubalisi reveals an active endocytic system

Research article published in Acta tropica (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Clinical LiteratureWang et al. · Acta tropica, 2025

Abstract

Trypanosoma bubalisi is a newly identified mammalian trypanosome isolated from a freshwater leech (Hirudinaria manillensis) and the water buffalo (Bubalus bubalis) is considered its host. Despite the detailed morphological description of in vitro cultivated forms of this trypanosome, little is known about its ultrastructure. In this study, a detailed ultrastructure of T. bubalisi was characterized using scanning electron microscopy, transmission electron microscopy and focused ion beam-scanning electron microscopy. Two membrane-bound organelles were identified, multivesicular body-like vesicles (ve1) and large lipid-rich vesicles resembling reservosomes (ve2), alongside an extracellular 'beads-on-a-string' structure. These all appear to be associated with endocytosis or secretion. Three-dimensional reconstructions confirmed the organization and distribution of the two membrane-bound organelles. Functional assays using Tomato lectin and Lyso-Tracker demonstrated that ve2 is involved in endocytic uptake and may act as a terminal storage compartment. Compared to the pathogen causing Nagana, Trypanosoma brucei, T. bubalisi showed higher endocytic activity under both 27 °C and 4 °C conditions. These findings suggest that T. bubalisi possesses an active endocytic system and may share conserved mechanisms of material transport and storage with the pathogen causing Chagas' disease, Tryponosoma cruzi.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsEndocytosisTrypanosomaMicroscopy, Electron, ScanningMicroscopy, Electron, TransmissionBuffaloesLeechesOrganelles

Summary

Scanning, transmission and focused ion beam electron microscopy of Trypanosoma bubalisi, a trypanosome isolated from the freshwater leech Hirudinaria manillensis, revealed two endocytosis-related organelles and an active endocytic system exceeding that of Trypanosoma brucei at both temperatures tested.

Context

This study characterized the fine structure of Trypanosoma bubalisi, a newly identified mammalian trypanosome, using electron microscopy and functional dye assays; it identified two membrane-bound organelles and reported higher endocytic activity than the Nagana pathogen T. brucei. Plainly, this is a parasitology and cell-biology paper, and the medicinal leech (Hirudinaria manillensis) appears only as the source organism the trypanosome was isolated from, not as a therapeutic agent. The work tells us nothing about hirudotherapy, the leech salivary secretome, or any anticoagulant or clinical effect, and its relevance to leech therapy is essentially a naming/host-biology overlap rather than a substantive connection. As a preclinical ultrastructural study of a protozoan parasite, it should not be read as evidence for or about medicinal-leech treatment.

Citation

Reference (Vancouver style)

Wang JF, Bi YX, Yang J, Hide G, Lai DH, Lun ZR. Ultrastructural and morphological characterization of Trypanosoma bubalisi reveals an active endocytic system. Acta Trop. 2025;272:107926. doi:10.1016/j.actatropica.2025.107926. PMID: 41318076

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.